• Passage Bio posted a net loss of $7.56 million for the three months ended March 31, 2026, narrowing from $15.41 million a year earlier.
• Operating loss improved to $8.25 million, while research and development expense fell to $4.09 million.
• General and administrative expense declined to $4.79 million, while other income eased to $688,000.
• Cash and cash equivalents totaled $33.3 million as of March 31, 2026, with management flagging substantial doubt about its ability to continue as a going concern within one year.
• Company launched a strategic alternatives review, announced a workforce cut of about 75%, and disclosed FDA feedback that a randomized controlled registrational study is required for PBFT02 in FTD-GRN.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-058987), on May 12, 2026, and is solely responsible for the information contained therein.